Researchers have developed an artificial intelligence-powered blood test capable of detecting a common, often silent liver condition years before symptoms typically appear. The test analyzes routine blood samples using machine learning algorithms to identify patterns indicative of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD. This condition, linked to obesity and diabetes, can progress to serious liver damage without noticeable warning signs. The AI model was trained on a large dataset of patient records and bloodwork, learning to spot subtle biomarkers that human doctors might overlook in standard tests. Early detection through this method could allow for lifestyle and medical interventions much sooner, potentially preventing irreversible liver scarring, cirrhosis, or cancer. The developers emphasize that the test is designed to be a low-cost, accessible screening tool for at-risk populations. Read the full article for more details on the clinical study and potential implementation.